Hear me out if you want to make some easy money and have OTC stock access. I know Fidelity allows it but not sure what other brokers do. Even if you don't, it will list Tues on Nasdaq and there will still be plenty of $$$ to be made. Be advised,
in my opinion that this is going to be a pump and dump but most think it will at least double in price. There are also a lot of people who plan on holding this long-term so I could be wrong on my pump and dump prediction.
MMEDF is currently a Canadian OTC stock but on Tues it is being listed on Nasdaq as MNMD. Shares purchased as MMEDF will change when listing is complete.
MMEDF is currently sitting at $3.52/share on the OTC market. I have a limit order of 1000 shares at market open Mon morning at the current price, but I'm debating on raising it a bit so I don't miss out.
It's a psychedelic medicine biotech company that studies how shrooms, LSD, and even MDMA and DMT can help treat depression. It already pumped up 65%+ on Fri when news of Nasdaq listing came out, but it still has plenty of room to pump because a LOT of people without OTC access will hit it hard on Tues. This already has a
HUGE following on Reddit, Stocktwits and Yahoo Finance. The best part is since it hasn't hit Nasdaq yet, it will be a week or so after listing before options so it cannot be shorted.
Quote:
With the upcoming Nasdaq listing of Mindmed(MNMD), I'm sure a lot of you are ready for the first ever "shroom boom" on the North american stock exchange. While tendies are definitely an outcome of this, there's more to it than that. I discovered Mindmed after seeing my dad live with PTSD/depression his whole life as well as having a good friend pass away because of an overdose, and have been behind their mission of combating mental health issues and ending the opioid addiction problem ever since.
A few statistics:
-92 Million people use opiods globally
-$500 Billion spent on opioids in the US alone
-There has been an 844% in benzodiazepine overdose deaths since 1999
-284 Million globally suffer from anxiety
-$4.7 Billion is spent on anxiety medication annually
Anxiety is growing as social media usage skyrockets. Since widespread social media adoption in 2009, there has been a 189% increase in self-harm. And now COVID-19 is causing job loss, isolation, and overall fear. Anxiety medications have increased 34.1% month-over-month in the first few months of COVID-19.
21 million Americans have at least one addiction, yet despite focused efforts in the space, which are saving lives on a daily basis, only 10% of those individuals receive treatment. Addiction is a brain disease, driven by a set of disease processes including the dysregulation of dopamine, a potent neurotransmitter, in the brain’s reward/pleasure center located in the midbrain.
Mindmed has plenty of catalysts down the pipeline that will bring tendies, but more importantly, it'll bring peace of mind to both those suffering from mental health disorders and those who have to sit on the sideline and watch their loved one go through it
A few projects currently on their timeline:
- Project Lucy: Project Lucy involves a hallucinogenic dosing of LSD to treat anxiety, administered by a therapist. LSD increases brain communication and supports talk therapy by expanding the mind and minimizing inhibitions. MindMed is currently preparing to initiate our Phase 2b human efficacy trial for experiential doses of LSD.
-18-MC: "We are developing 18-MC to treat the cause of the brain disease that is addiction, rather than solely the symptoms. Sustained mental healing requires addressing a root cause and a comprehensive approach for the entire patient journey. Cue-induced reinstatement, or relapse, is when an individual with a substance use disorder is prompted by their surroundings to consume a harmful substance (example: The clink of a wine glass at a dinner party for a person with an alcohol use disorder)." Currently in phase 1B FDA trials.
While this is still a very new form of pharma, this has potential to be the new wave of mental health treatment. With Biden pushing heavy for the end of opioid addiction, Mindmed is armed and ready to take on that task.
Buying and holding this will put MindMed on the map for more people who are unfamiliar with this revolutionary treatment. We all saw what a bunch of degenerates could do to multi-billion dollar Hedge funds. Now lets see what we can do to deadly mental "diseases" and Big pharma who's making profit from the chaos.
TL;DR:
Addiction/depression is one of the leading causes of death in the US, Mindmed is creating safe ways to combat these. Medication for these alone pulls in over $500B annually.
Huge tendie potential as Mindmed is the first to pioneer psychedelic medication/therapy.
Huge potential to save friends and family from suffering from addiction/depression.
|
https://www.reddit.com/r/wallstreetb..._mindmed_mnmd/
My TL;DR:
A lot of money will pump in the stock when it hits Nasdaq Tues so there will be good money to be made. Even more money will be made if you have OTC stock access and can buy in Monday.